REVIEW ARTICLE
Oncology
doi: 10.25005/2074-0581-2026-28-3-750-770
CURRENT PERSPECTIVES ON SUPPORTIVE CARE IN ONCOLOGY

M.R. NURITDINZODA1, D.R. SANGINOV1, O.KH. KHUSHKADAMOVA1,2, I.K. NIYAZOV1,2

1Department of Oncology, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan
2Republican Oncology Scientific Center, Dushanbe, Republic of Tajikistan

This article summarizes data from systematic reviews, meta-analyses, and clinical guidelines (ASCO, ESMO, MASCC, NCCN, RUSSCO) published between 2020 and 2025, emphasizing interdisciplinary and personalized approaches. The literature search was conducted systematically in accordance with PRISMA recommendations. PubMed, Scopus, Web of Science, and the Russian Science Citation Index (RSCI; eLibrary.ru) databases were searched. The search period was defined as January 1, 2018, to August 1, 2025. Search strategies for publications in English and Russian included the keywords “supportive care”, “chemotherapy-induced nausea and vomiting”, “febrile neutropenia”, “cardiotoxicity”, “personalized oncology”, “immune-related adverse events”, “oncology guidelines”, “CIPN”, and others, combined using Boolean operators (AND, OR) to maximize literature coverage. A total of 4,936 records were identified; after filtering, duplicate removal, and preliminary screening of irrelevant records, 43 articles were included in the review.

International and Russian studies were compared, gaps in the standardization of supportive care protocols were identified, and several promising directions were outlined. These include the introduction of new antiemetic regimens incorporating olanzapine; broader use of granulocyte colony stimulating factors (G-CSFs) and their biosimilars for the prevention of neutropenia; the use of duloxetine for the treatment of painful neuropathy; further investigation of dexrazoxane and cardio-oncology monitoring for the prevention of anthracycline-induced cardiotoxicity; and the use of hepatoprotective agents and mannitol to reduce the risk of organ toxicity. The findings underscore the need to develop national algorithms and to widely implement multidisciplinary strategies for the management of patients with treatment-related toxicities.

Keywords: Supportive care, chemotherapy-induced nausea and vomiting, febrile neutropenia, anemia, neuropathy, cardiotoxicity..

Download file:

References
  1. Scotté F, Taylor A, Davies A. Supportive care: The "keystone" of modern oncology practice. Cancers (Basel). 2023;15(15):3860. https://doi.org/10.3390/ cancers15153860
  2. Kennedy SKF, Goodall S, Lee SF, DeAngelis C, Jocko A, Charbonneau F, et al. 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 2024;32(5):280. https://doi. org/10.1007/s00520-024-08462-x
  3. Bozzini C, Busti F, Marchi G, Vianello A, Cerchione C, Martinelli G, et al. Anemia in patients receiving anticancer treatments: Focus on novel therapeutic approaches. Front Oncol. 2024;14:1380358. https://doi.org/10.3389/fonc.2024.1380358
  4. Higuchi K, Yanagawa T. Evaluating dose of cisplatin responsible for causing nephrotoxicity. PLoS One. 2019;14(4):e0215757. https://doi.org/10.1371/ journal.pone.0215757
  5. Schaper T, Gross B, Franzmann L, Darsow M. Using a new controlled thermotherapy (Hilotherapy®) during chemotherapy prevents chemotherapy induced polyneuropathy (CIPN). Ann Oncol. 2020;31(2):S83-S84. https://doi. org/10.1016/j.annonc.2020.03.125
  6. Wang D-Y, Chen Y, Zhang Y and Shen Y-Q. The balance between the effectiveness and safety for chemotherapy-induced nausea and vomiting of different doses of olanzapine (10 mg versus 5 mg): A systematic review and meta-analysis. Front. Oncol. 2021;11:705866. https://doi.org/10.3389/fonc.2021.705866
  7. Aapro M, Scotté F, Escobar Y, Celio L, Berman R, Franceschetti A, et al. Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist. 2021;26(6):e1073-e1082. https://doi.org/10.1002/onco.13716
  8. Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. Oncologist. 2019;24(6):e347-e357. https://doi.org/10.1634/theoncologist.2018-0140
  9. Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, et al. Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open. 2024;7(8):e2426076. https://doi.org/10.1001/jamanetworkopen.2024.26076
  10. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-97. https://doi. org/10.1200/JCO.20.01296
  11. Orlova RV, Gladkov OA, Kutukova SI, Kopp MV, Korolyova IA, Larionova VB, i dr. Prakticheskie rekomendatsii po lecheniyu anemii pri zlokachestvennykh novoobrazovaniyakh (RUSSCO, 2021) [Practical recommendations for the treatment of anemia in malignant neoplasms (RUSSCO, 2021)]. Zlokachestvennye opukholi. 2021;11(3s2):36-43. https://doi.org/10.18027/2224-5057-2021- 11-3s2-36
  12. Sakaeva DD, Borisov KE, Bulavina IS, Kogoniya LM, Kurmukov IA, Orlova RV, Shabaeva MM. Prakticheskie rekomendatsii po diagnostike i lecheniyu febril'noy neytropenii [Practical recommendations for the diagnosis and treatment of febrile neutropenia]. Zlokachestvennye opukholi. 2021;11(3s2-2):55-63. https:// doi.org/10.18027/2224-5057-2021-11-3s2-39
  13. Borgeaud M, Perano S, Addeo A, Tsantoulis P. Rates of febrile neutropenia and its causes in the real world. Future Oncol. 2024;20(29):2203-12. https://doi.org/10. 1080/14796694.2024.2349510
  14. Wang W, Li E, Campbell K, McBride A, D'Amato S. Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the Oncology Care Model Framework. JCO Oncol Pract. 2021;17(8):e1139-e1149. https://doi.org/10.1200/OP.20.00994
  15. Saad ESP, Oualla K, Talibova N, Gening S, YousefYousef SG. Afebrile chemotherapyinduced neutropenia: an international survey spots oncologists' routine clinical practice versus the standard of care and the impact of COVID-19. Support Care Cancer. 2022;30(12):9921-8. https://doi.org/10.1007/s00520-022-07421-8
  16. Moir H. The role of granulocyte-colony stimulating factor biosimilars for supportive cancer care: Ф year in review. EMJ. 2023;8(1):16-24. https://doi. org/10.33590/emjoncol/10305851
  17. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesisstimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336-51. https://doi.org/10.1200/JCO.18.02142
  18. Heregger R, Greil R. Erythropoiesis-stimulating agents – Benefits and harms in the treatment of anemia in cancer patients. Memo. 2023;16:259-62. https://doi. org/10.1007/s12254-023-00902-4
  19. Bogomolova IA, Udalov YuD, Belova LA, Danilova LA, Kozlova IV, Kuvayskaya AA. Sovremennoe sostoyanie problemy, vozmozhnosti lecheniya perifericheskoy polineyropatii i reabilitatsii patsientov s kolorektal'nym rakom, poluchayushchikh khimioterapiyu na osnove preparatov platiny [Current state of the problem, possibilities of treating peripheral polyneuropathy and rehabilitation of patients with colorectal cancer receiving platinum-based chemotherapy]. Povolzhskiy onkologicheskiy vestnik. 2023;14(2):73-80. https://doi.org/10.32000/2078- 1466-2023-2-73-80
  20. Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, et al. Updates in the treatment of chemotherapy-induced peripheral neuropathy. Curr Treat Options Oncol. 2022;23(1):29-42. https://doi. org/10.1007/s11864-021-00926-0
  21. D'Souza RS, Alvarez GAM, Dombovy-Johnson M, Eller J, Abd-Elsayed A. Evidencebased treatment of pain in chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep. 2023;27(5):99-116. https://doi.org/10.1007/s11916-023- 01107-4
  22. Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, et al. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): Systematic review and meta-analysis. BMJ Support Palliat Care. 2023;13(1):27-34. https://doi.org/10.1136/spcare-2022-003815
  23. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. https://doi.org/10.3389/fcvm.2020.00026
  24. Gent DG, Rebecca D. The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. Eur Cardiol. 2023;18:e16. https://doi.org/10.15420/ ecr.2022.63
  25. Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology State-of-theArt Review. JACC CardioOncol. 2024;6(5):655-77. https://doi.org/10.1016/j. jaccao.2024.07.016
  26. Sotiropoulou IM, Manetas-Stavrakakis N, Kourek C, Xanthopoulos A, Magouliotis D, Giamouzis G, et al. Prevention of anthracyclines and HER2 inhibitor-induced cardiotoxicity: A systematic review and meta-analysis. Cancers (Basel). 2024;16(13):2419. https://doi.org/10.3390/cancers16132419
  27. Vitsenya MV, Ageev FT, Orlova RV, Poltavskaya MG, Potievskaya VI. Prakticheskie rekomendatsii po korrektsii kardiovaskulyarnoy toksichnosti protivoopukholevoy lekarstvennoy terapii. Prakticheskie rekomendatsii RUSSCO, chast' 2 [Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Practical recommendations RUSSCO, part 2]. Zlokachestvennye opukholi. 2023;13(3s2):83-107. https://doi.org/10.18027 / 2224-5057-2023-13-3s2- 2-83-107
  28. Tkachenko PE, Ivashkin VT, Maevskaya MV. Klinicheskie rekomendatsii po korrektsii gepatotoksichnosti, indutsirovannoy protivoopukholevoy terapiey [Clinical guidelines for the correction of hepatotoxicity induced by antitumor therapy]. Zlokachestvennye opukholi. 2021;11(3s2-2):64-77. https://doi. org/10.18027/2224-5057-2021-11-3s2-40
  29. Chen C, Xie D, Gewirtz DA, Li N. Nephrotoxicity in cancer treatment: An update. Adv Cancer Res. 2022;155:77-129. https://doi.org/10.1016/bs.acr.2022.03.005
  30. Shatila M, Zhang HC, Shirwaikar Thomas A, Machado AP, Naz S, Mittal N, et al. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer. 2024;12(11):e009742. https://doi.org/10.1136/jitc-2024-009742
  31. Kamyshova ES, Bobkova IN, Sekacheva MI. Porazhenie pochek, assotsiirovannoe s protivoopukholevoy terapiey: fokus na nezhelatel'nye yavleniya sovremennykh immunoonkologicheskikh preparatov [Kidney damage associated with antitumor therapy: Focus on adverse events of modern immuno-oncological drugs]. Terapevticheskiy arkhiv. 2021;93(6):649-60. https://doi.org/10.26442/00403660.20 21.06.200860
  32. Kala J, Joseph T, Pirovano M, Fenoglio R, Cosmai L. Acute kidney injury associated with anticancer therapies: small molecules and targeted therapies. Kidney360. 2024;5(11):1750-62. https://doi.org/10.34067/KID.0000000566
  33. Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(7):3461-74.
  34. Li S, He X, Ruan L, Ye T, Wen Y, Song Z, et al. Protective effect of mannitol on cisplatin-induced nephrotoxicity: A systematic review and meta-analysis. Front Oncol. 2021;11:804685. https://doi.org/10.3389/fonc.2021.804685
  35. Liu Z, Yuan D, Chang J, Shi L, Li J, Zhao M, Yang Q. The effect of prophylactic hepatoprotective therapy on drug-induced liver injury in patients undergoing chemotherapy for cervical cancer: A retrospective analysis based on propensity score matching. Curr Oncol. 2025;32(7):393. https://doi.org/10.3390/ curroncol32070393
  36. Olver I, Keefe D, Herrstedt J, Warr D, Roila F, Ripamonti CI. Supportive care in cancer-a MASCC perspective. Support Care Cancer. 2020;28(8):3467-75. https:// doi.org/10.1007/s00520-020-05447-4
  37. Neves K. Implementing a validated multi-symptom assessment tool during telephone triage to reduce oncology patient emergency room visits. J Adv Pract Oncol. 2024:1-8. https://doi.org/10.6004/jadpro.2024.15.8.12
  38. Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, et al. Digital health for optimal supportive care in oncology: Benefits, limits, and future perspectives. Support Care Cancer. 2020;28(10):4589-612. https://doi.org/10.1007/s00520- 020-05539-1
  39. Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28(12):6159-73. https://doi.org/10.1007/s00520-020- 05710-8
  40. Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotté F, Strasser F, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol. 2018;29(1):36-43. https://doi.org/10.1093/annonc/mdx757
  41. Vladimirova LYu, Gladkov OA, Korolyova IA, Rumyantsev AA, Semiglazova TYu, Tryakin AA, i dr. Prakticheskie rekomendatsii po profilaktike i lecheniyu toshnoty i rvoty u onkologicheskikh bol'nykh [Practical recommendations for the prevention and treatment of nausea and vomiting in cancer patients]. Zlokachestvennye opukholi. 2021;11(3s2-2):25-38. https://doi.org/10.18027/2224- 5057-2021-11-3s2-37
  42. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-48. https://doi.org/10.1200/JCO.20.01399
  43. Tuominen L, Leino-Kilpi H, Poraharju J, Cabutto D, Carrion C, Lehtiö L, et al. Interactive digital tools to support empowerment of people with cancer: A systematic literature review. Support Care Cancer. 2024;32(6):396. https://doi. org/10.1007/s00520-024-08545-9

Authors' information:

Nuritdinzoda Manzura Rustam,
Postgraduate Student, Department of Oncology, Avicenna Tajik State Medical University
ORCID ID: 0009-0005-9025-6775
SPIN: 3044-6793
E-mail: ibadullaeva.manzura@mail.ru

Sanginov Dzhumaboy Rakhmatovich,
Doctor of Medical Sciences, Full Professor, Professor of the Department of Oncology, Avicenna Tajik State Medical University
Researcher ID: AAH-2351-2021
Scopus ID: 58758943100
ORCID: 0000-0002-4311-3094
SPIN: 3535-1025
Author ID: 1099938
E-mail: sanginov1952@gmail.com

Khushkadamova Oftob Khushkadakmovna,
Assistant Professor, Department of Oncology, Avicenna Tajik State Medical University; Oncologist, Chemotherapy and Palliative Care Department, Republican Oncology Scientific Center
ORCID ID: 0009-0003-2639-4781
E-mail: sun_0090@mail.ru

Niyazov Ilhomidin Karimovich,
Candidate of Medical Sciences, Assistant Professor, Department of Oncology, Avicenna Tajik State Medical University; Oncologist, Department of General Oncology, Republican Scientific Oncology Center
Researcher ID: AAH-2357-2021
ORCID ID: 0000-0002-2361-043X
SPIN: 1212-0435
Author ID: 805452
E-mail: ilhomnike@mail.ru

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Nuritdinzoda Manzura Rustam
Postgraduate Student, Department of Oncology, Avicenna Tajik State Medical University

734026, Republic of Tajikistan, Dushanbe, Sino str., 29-31

Tel.: +992 (933) 336781

E-mail: ibadullaeva.manzura@mail.ru


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. COMPREHENSIVE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER: THE ROLE OF NEOADJUVANT INTRA-ARTERIAL CHEMOTHERAPY
  2. CARDIOTOXICITY OF CHEMOTHERAPEUTIC AGENTS
  3. IMMUNOLOGICAL PROFILE OF SEROUS OVARIAN CARCINOMA AND DUCTAL BREAST CARCINOMA
  4. CLINICAL AND MORPHOLOGICAL FEATURES AND CYTOKINE STATUS ASSESSMENT IN THYROID CANCER
  5. EVALUATION OF THE EFFICIENCY OF COMBINED TREATMENT OF PATIENTS WITH BONE METASTASES FROM KIDNEY AND PROSTATE CANCER USING SYSTEMIC RADIATION AND TARGETED THERAPY
  6. INCIDENCE OF MULTIPLE PRIMARY MALIGNANT NEOPLASMS IN SIBERIA AND THE FAR EAST
  7. SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER: ONGOING CONSIDERATIONS
  8. ROLE OF RADIATION THERAPY IN COMBINED AND MULTIMODAL TREATMENT OF T3-4N1-2-3M0-1-2 STAGE SKIN CANCER
  9. SURGICAL TREATMENT OF A GIANT RETROPERITONEAL LIPOMA: A CLINICAL CASE
  10. PREOPERATIVE PREDICTION OF WALL INVASION DEPTH OF PRIMARY TUMOR (PT) IN GASTRIC CANCER PATIENTS

◄ Back to the list